Hainan Huluwa Pharmaceutical Group Co., Ltd. (605199.SS)
CNY 19.25
(-3.12%)
CNY 19.25
(-3.12%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 1.28 Billion CNY | 87.38% |
| 2022 | 683.98 Million CNY | 37.01% |
| 2021 | 499.21 Million CNY | 76.39% |
| 2020 | 283.01 Million CNY | 85.44% |
| 2019 | 152.62 Million CNY | 7.41% |
| 2018 | 142.09 Million CNY | -2.88% |
| 2017 | 146.3 Million CNY | -35.92% |
| 2016 | 228.31 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q3 | 1.35 Billion CNY | -24.59% |
| 2024 Q2 | 1.37 Billion CNY | 7.2% |
| 2024 Q1 | 1.28 Billion CNY | 0.43% |
| 2023 Q3 | 1.11 Billion CNY | 16.88% |
| 2023 Q2 | 955.59 Million CNY | 20.9% |
| 2023 FY | 1.28 Billion CNY | 87.38% |
| 2023 Q1 | 790.39 Million CNY | 15.56% |
| 2023 Q4 | 1.28 Billion CNY | 14.75% |
| 2022 Q4 | 683.98 Million CNY | 30.51% |
| 2022 Q3 | 524.08 Million CNY | 4.83% |
| 2022 Q2 | 499.92 Million CNY | 22.23% |
| 2022 Q1 | 408.99 Million CNY | -18.07% |
| 2022 FY | 683.98 Million CNY | 37.01% |
| 2021 Q1 | 334.77 Million CNY | 18.29% |
| 2021 Q4 | 499.21 Million CNY | 31.83% |
| 2021 FY | 499.21 Million CNY | 76.39% |
| 2021 Q2 | 293.16 Million CNY | -12.43% |
| 2021 Q3 | 378.68 Million CNY | 29.17% |
| 2020 Q2 | 257.79 Million CNY | 14.7% |
| 2020 Q4 | 283.01 Million CNY | -9.69% |
| 2020 FY | 283.01 Million CNY | 85.44% |
| 2020 Q3 | 313.39 Million CNY | 21.57% |
| 2020 Q1 | 224.75 Million CNY | 47.26% |
| 2019 Q2 | 145.39 Million CNY | 0.0% |
| 2019 FY | 152.62 Million CNY | 7.41% |
| 2019 Q1 | - CNY | 0.0% |
| 2019 Q4 | 152.62 Million CNY | 0.0% |
| 2018 FY | 142.09 Million CNY | -2.88% |
| 2017 FY | 146.3 Million CNY | -35.92% |
| 2016 FY | 228.31 Million CNY | 0.0% |